32 results about "Autosomal dominant polycystic kidney disease" patented technology

The invention discloses application of ginkgolide B to preparation of medicament for preventing and / or treating autosomal dominant polycystic kidney disease. A madin-darby canine kidney (MDCK) vesicle model is used for screening to find that the ginkgolide B inhibits formation and growth of vesicles. An experimental result shows that: the ginkgolide B has an obvious inhibiting effect on the formation and growth of MDCK vesicles and the effect of the ginkgolide B is in dose response relationship; the ginkgolide B has no cytotoxicity to MDCK cells, so that the vesicle inhibiting effect of the ginkgolide B is independent of the cytotoxicity; the ginkgolide B does not obviously induce MDCK cell apoptosis, so that the vesicle inhibiting effect of the ginkgolide B is independent of cell apoptosis promotion of the ginkgolide B; the ginkgolide B can promote the MDCK cells or vesicles to form tubular structures; and the effect is in dose response relationship; and the ginkgolide B has an inhibiting effect on the growth of the embryonic kidney vesicles. The ginkgolide B provides experimental data for development of a specific medicament for preventing and / or treating autosomal dominant polycystic kidney disease.

Disclosed are methods for treating kidney disease including autosomal dominant polycystic kidney disease (ADPKD) in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of ticagrelor or a derivative thereof, thereby treating ADPKD. Disclosed are methods of decreasing arginine vasopressin (AVP) production in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production. Disclosed are methods for treating dilutional hyponatremia in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production.

A new type of kidney miniature organoids based on human embryonic stem cells are prepared and tested as forming cysts in vitro or ex vivo. Assays are developed for screening useful candidate molecules towards inhibiting or treating polycystic kidney disease. This provides a new system for modeling polycystic kidney disease.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Compounds of formula (I), wherein the groups are as defined in the specification, are very useful for the preparation of medicaments for the treatment of cardiovascular disorders, especially heart failure and hypertension. These compounds are inhibitors of the enzymatic activity of Na+, K+-ATPases. They are very useful for the manufacture of medicaments for the treatment of diseases caused by the hypertensive effects of endogenous ouabain, such as progression of renal failure in autosomal dominant polycystic kidney disease (ADPKD), preeclamptic hypertension and protein Urine and renal failure progression in patients with adducin polymorphisms.

The invention belongs to a technology of medical in vitro diagnosis, and in particular relates to an amplification primer for detecting mutation of autosomal dominant polycystic kidney disease-causing gene PKD2 as well as a detection method. The amplification primer, in accordance with the sequence information of the PKD2 gene, designs four pairs of PCR primers; the PKD2 is subjected to targeted amplification by virtue of long-chain PCR; and an amplification region includes all exon sequences and most intron sequences, as well as partial 5' untranslated region sequences and 3' untranslated region sequences. According to the method, by combining long-chain PCR targeted amplification to the newest developed next generation of sequencing technology, a targeted sequencing process is simplified, the scope and flux of detecting the PKD2 gene mutation are improved, a detection cycle is shortened and cost is reduced.

The invention discloses STR sites of a PKD2 gene. The STR sites are selected from nucleotide sequences as show in SEQ ID NO.1-SEQ ID NO.6. The invention also discloses an application of the STR sites of the PKD2 gene, wherein the STR sites are applicable to preimplantation genetic diagnosis or prenatal disgnosis of autosomal dominant polycystic kidney disease. The STR sites of the PKD2 gene are higher in resolution ratio; and the STR sites, when applied to linkage genetic analysis of the PKD2 gene, can significantly improve typing recognition efficiency and accuracy; therefore, a basis is provided for the clinical preimplantation genetic diagnosis of the autosomal dominant polycystic kidney disease.

Methods for treating autosomal dominant polycystic kidney disease (ADPKD) are described herein. More particularly, methods described herein relate generally to administering glutaminase1 inhibitors to subjects afflicted with ADPKD. Accordingly, the use and application of compounds or agents that inhibit glutaminase1 for treating ADPKD or for use in a medicament for treating ADPKD are encompassed herein.

The invention discloses an aminoalcohol compound, its preparation method, a pharmaceutical composition containing the compound and an application of the compound. The structure of the compound is as shown in the general formula (I), wherein A, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and the claims. The compound provided by the invention can be used in the preparation of drugs for preventing and / or treating autosomal dominant polycystic kidney disease.

A method for diagnosing a predisposition for accelerated autosomal dominant polycystic kidney disease (ADPKD) in a human male subject by detecting the Glu 298 Asp polymorphism of the ENOS gene is described. A diagnostic kit for detecting predisposition for accelerated ADPKD in a human subject is also disclosed. In addition, a method for treating a human subject predisposed to develop accelerated APDKD using NO-enhancing compounds is provided.

The invention relates to the application of pyrimidine (thio) ketone compounds in the preparation of medicines for treating secretory diarrhea and autosomal dominant hereditary polycystic kidney disease. Cystic fibrosis transmembrane conductance regulator is a Cl-channel protein activated by cyclic adenosine monophosphate. During the design of the model, multiple activation pathways of CFTR were considered, and multiple activation pathways were combined to screen During the process, it binds at the Cl-transport channel. The application of pyrimidine (thio) ketone compounds in the preparation of drugs for treating secretory diarrhea and autosomal dominant polycystic kidney disease is screened on the basis of screening a large number of compounds by using the model for screening inhibitors directly combined with CFTR. It can effectively prevent and treat the occurrence of swine diarrhea. Effectively inhibits fluid secretion from epithelial cells lining autosomal dominant polycystic kidney cysts. The inhibitory effect is rapid, and there is no obvious toxic effect.

The invention provides the application of 1-indanone in the preparation of medicine for treating or preventing autosomal dominant polycystic kidney disease. The present invention uses the MDCK vesicle model to prove that 1-indanone can inhibit the formation and growth of vesicles, and determines the renal pharmacological activity of 1-indanone through the in vitro embryonic kidney vesicle model, which has a significant effect on the development of vesicles in the kidney. Finally, it was further proved in the polycystic kidney mouse model that 1-indanone also had the effect of inhibiting the occurrence and development of vesicles in vivo. The above-mentioned vesicle inhibitory effects in vitro and in vivo showed a dose-effect relationship.